Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Interviews and Video Capture in Patients With GM1 Gangliosidosis
- Conditions
- GM1 Gangliosidosis
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- LYSOGENE
- Target Recruit Count
- 25
- Registration Number
- NCT04310163
- Locations
- 🇺🇸
Casimir Trials, Plymouth, Massachusetts, United States
A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis
- Conditions
- GM1 Gangliosidosis
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- LYSOGENE
- Target Recruit Count
- 5
- Registration Number
- NCT04273269
- Locations
- 🇺🇸
Children's Hospital of Orange County (CHOC), Orange, California, United States
🇫🇷Hôpital Armand-Trousseau, Centre de Référence des Maladies Lysosomales (CRML), Service de Neuropédiatrie, Paris, France
🇬🇧Manchester University NHS Foundation Trust, Manchester, United Kingdom
Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- LYSOGENE
- Target Recruit Count
- 20
- Registration Number
- NCT03612869
- Locations
- 🇺🇸
CHOC Children's, Orange, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Natural History Study of Patients With MPS IIIA
- Conditions
- Mucopolysaccharidosis IIIA
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- LYSOGENE
- Target Recruit Count
- 23
- Registration Number
- NCT02746341
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
🇫🇷Armand Trousseau Public Hospital, Paris, France
🇩🇪University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy
- Conditions
- Mucopolysaccharidosis Type III ASanfilippo Disease Type A
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- LYSOGENE
- Target Recruit Count
- 4
- Registration Number
- NCT02053064
- Locations
- 🇫🇷
Hôpitaux Universitaires Paris Sud (Bicêtre), Le Kremlin-Bicêtre, France
- Prev
- 1
- 2
- Next